ZYVOX should only be initiated in a hospital environment and after consultation with a relevant specialist such as a microbiologist or infectious diseases specialist1.
After nearly 20 years of infection control, documented long-term in vitro potency with ZYVOX continues2
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
AMR, antimicrobial resistance; E. faecium, Enterococcus faecium; E.faecalis, Enterococcus faecalis; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; S.pneumoniae, Streptococcus pneumoniae
- ZYVOX® Summary of Product Characteristics
- Mendes RE, et al. ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries. J Antimicrob Chemother. 2018; 73(7): 1880-1887